Josh Horhey

PHD Doctor of Philosophy,  Mayo Clinic - Rochester 

Location: Africa

Consulting Services

Case Consulting Data Science-Bioinformatics Hospital-Pharmacy-Insurance Biostatistics

Areas Of Interest

Supervision Lymphomatoid Granulomatosis Small-Cell Lymphoma, Centrocytic guyanensis, Leishmania braziliensis Prior Authorizations Myeloproliferative Leukemia Virus Oncogene Ligand Receptor Agonists, Cannabinoid Neoplasm, Hormone-Dependent Latency-Associated Protein, TGF-beta2 Catheter, Ureteral Physicians' Assistant SelR Protein Macropus robustus Sperm Capacitation Blood Coagulation Factor Prolapses Toxin Receptors, Diphtheria Hybrid, Radiation Promotion, Vaccination Traumatic Intracranial Hemorrhages Manipulative Medicine, Osteopathic Angioplasty, Laser-Assisted, Balloon beta-Transducin Corneoscleral Junction RNA Polymerase, DNA-Directed Ulcer, Stasis Infiltration, Neutrophil Injury, TASER PEEP, Occult Cysts, Arachnoid Coronavirus, Rabbit Carboxycellulose Prepiriform Cortices Sparteine, (7S-(7alpha,7abeta,14alpha,14abeta))-Isomer Continuous RRT

Professional Narrative

Dr. Josh Horhey was born in DuBois, Pennsylvania and is a graduate of Villanova University. He obtained his medical degree at Thomas Jefferson University in Philadelphia. His residency was at Thomas Jefferson and its affiliated Wills Eye Hospital, and he completed his training with fellowships at the University of Connecticut incataract andcorneal surgery.

Dr. Horhey has thirty years’ experience in ophthalmic surgery,withspecialinterestin cataract surgery,corneal transplantation,andlaserrefractiveprocedures.Heisa founding member of Precision LASIK Group, Chief of Ophthalmology at The Hospital ofCentral Connecticut,andco-medical director of the Connecticut eye bank.


Employment

Executive Director, Harvard Med 1987
Director Medicine, Harvard Med 1991

Education

Doctor of medicine, Perelman School of Medicine 2018
Bachelor of science in nursing, Yale School of Medicine 1988

Referees


Publications

Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019 Mar;18(3):175-196. doi: 10.1038/s41573-018-0006-z. PMID: 30622344; PMCID: PMC6410566.

Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020 Oct;19(10):673-694. doi: 10.1038/s41573-020-0075-7. Epub 2020 Aug 11. PMID: 32782413; PMCID: PMC7419031.

Yin X, Mead BE, Safaee H, Langer R, Karp JM, Levy O. Engineering Stem Cell Organoids. Cell Stem Cell. 2016 Jan 7;18(1):25-38. doi: 10.1016/j.stem.2015.12.005. PMID: 26748754; PMCID: PMC4728053.

Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021 Feb;20(2):101-124. doi: 10.1038/s41573-020-0090-8. Epub 2020 Dec 4. PMID: 33277608; PMCID: PMC7717100.


Grants,Awards and Certifications

Grants :

No Grants Mentioned !!

Awards & Prizes :


Languages

Language Proficiency :

Translation Services :